抗Xa因子在高风险患者群体中抗凝给药的监测作用  

A Study of Monitoring Effect of Anti-Xa Factor on Anticoagulation Administration in High-risk Patients

作　　者：李雪 杨卫 李永旺[2] 戴冬雪[2] 马蓓洁 张静波[2] 蔡会欣[2] LI Xue;YANG Wei;LI Yongwang;DAI Dongxue;MA Beijie;ZHANG Jingbo;CAI Huixin(Graduate School of Chengde Medical College,Chengde 067000,China;Baoding First Central Hospital,Baoding,071000,China)

机构地区：[1]承德医学院研究生学院,河北承德067000 [2]保定市第一中心医院,河北保定071000

出　　处：《标记免疫分析与临床》2024年第2期387-392,共6页Labeled Immunoassays and Clinical Medicine

摘　　要：静脉血栓栓塞症(VTE)是全世界重点关注的公共健康问题,由于其较高的发病率与致死率,国内外多项VTE防治指南提出了预防策略,但仍有VTE事件的发生。低分子肝素(LMWH)是临床上目前抗凝的首要选择,监测其抗凝疗效,可以降低血栓发生的风险。研究表明抗Xa活性水平可以很好地评估LMWH的抗凝效果,本文将对特殊人群在预防性抗凝治疗中抗Xa因子指标的作用进行综述,评估抗Xa因子监测抗凝用药的安全性和有效性。Venous thromboembolism(VTE)is a world-wide public health problem.Due to its high incidence rate and mortality,many prevention and treatment guidelines for VTE at home and abroad have been proposed for prevention purpose,but VTE events remain as a significant issue.Low molecular weight heparin(LMWH)is currently the primary choice for anti-coagulation in clinical practice.Monitoring its anti-coagulant efficacy can reduce the risk of thrombosis.Previous research has shown that the level of anti-Xa activity can effectively evaluate the anti-coagulant effect of LMWH,This article reviews the role of anti-Xa,an indicators in preventive anti-coagulant therapy in special populations,and evaluates the safety and effectiveness of anti-Xa for monitoring anti-coagulant therapy.

关 键 词：抗XA因子 静脉血栓栓塞症 低分子肝素 

分 类 号：R364.1[医药卫生—病理学]